XL281 News
Most Popular XL281 Story
Glaxo leaves Exelixis drugs behind as pact ends
Exelixis' six-year collaboration with GlaxoSmithKline has come to the end of the line with Glaxo deciding to bow out without licensing any of the drugs in the program. Exelixis retains the rights Read more...
Latest Headlines
- December 12, 2008
- October 23, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
